Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Comment by Francine01on Aug 31, 2020 10:15am
257 Views
Post# 31478880

RE:RE:Francine

RE:RE:Francine Indeed sad morning.

I still do believe that Capre works because 38.4% HTG after 26 weeks, is not the act god. 

The only information that we have is primary end point 12 weeks. 

This morning, we have 0 information, the placebo 17,9% reduction. Is it the average of weeks -2, -1 and 0 or at week 0 ? 

They didn't not control the enrolment background and patients were not stabilized before randomzation.

This is a story of trial incorrectly managed by Acasti management and CRO.

Board should seek for a financial advisor to review all stategic options. Since I am based in Montreal, I could coordinate on behalf of shareholders. I will talk to other shareholders in the followind days. 

I don't see Jan be part of any plan. Shareholders meeting is end of September, Jan should resign to avoid the disgrace of beeing kick out. 

The company is bassicaly trading for cash in bank account. There is no point for shareholders to sold shares. 

PS. boozer. I didn't sold any share. 



<< Previous
Bullboard Posts
Next >>